brazikumab   Click here for help

GtoPdb Ligand ID: 9293

Synonyms: AMG 139 | AMG-139 | MEDI2070
Immunopharmacology Ligand
Compound class: Antibody
Comment: Brazikumab (AMG 139, MEDI2070) is a fully human anti-IL23A monoclonal antibody in clinical development for autoimmune indications.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST peptide anaylsis reveals identical matches with peptides claimed in patent WO2011056600 [3].
1. Ahern PP, Izcue A, Maloy KJ, Powrie F. (2008)
The interleukin-23 axis in intestinal inflammation.
Immunol Rev, 226: 147-59. [PMID:19161422]
2. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W, Kwan S, Churakova T et al.. (2003)
Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain.
Nature, 421 (6924): 744-8. [PMID:12610626]
3. Towne JE, Cheng JD, O'neill JC, Zhang Y, Sun Y, Cerne H, Piper DE, Ketcherm RR. (2011)
Human il-23 antigen binding proteins.
Patent number: WO2011056600. Assignee: Amgen Inc.. Priority date: 26/10/2009. Publication date: 12/05/2011.